Skip to main content
OpenTrials
Completed

NCT Number: NCT00562614

Safety and Effect of Oral Doses of 5mg or 10mg of SLx-2101 for 14 Days in Patients With Hypertension

The purpose is to determine the effect of SLx-2101 dosed at 5mg or 10mg for 14 days on systolic, diastolic pressures and heart rate in patients with hypertension.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Hypertension Cardiovascular Diseases Vascular Diseases

Age range

18 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Parexel, Institute for Clinical Pharmacology

Berlin, D-14050, Germany

About this study

  • Placebo-corrected supine peripheral systolic, diastolic blood pressures and heart rate
  • 24 hour ambulatory blood pressure and heart rate
  • Safety and tolerability

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male or female subjects between 18 and 70 years old, inclusive
  • Moderate to severe hypertension
  • Body weight within a body mass index of 18-32kg/m2

Exclusion criteria

  • The subject is receiving more than three antihypertensive agents
  • A history of drug abuse
  • Exposure to a new chemical entity within 3 months prior to the first day of dosing

Treatment and study plan

SLx-2101

Drug

Primary outcomes

  1. Peripheral systolic, diastolic blood pressures and heart rates

    Time frame: 14 days

Secondary outcomes

  1. Adverse events

    Time frame: 14 days

Sponsors and collaborators

Lead sponsor

Retension Pharmaceuticals. Inc.

Industry

Registry information

Official study title

A Pilot Phase IIa Randomised, Double-blind, Placebo-controlled, Crossover Study to Examine the Safety, Tolerability and Pharmacodynamic Effects on Blood Pressure of Repeat Oral Doses of SLx-2101 5 mg or 10 mg Once Daily for up to 14 Days in Patients With Hypertension

Important dates

Study start
2007
Primary completion
2007
Study completion
2007
First posted
Nov 22, 2007
Registry last updated
Apr 30, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.